1. Home
  2. CSTL vs AEVA Comparison

CSTL vs AEVA Comparison

Compare CSTL & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$29.72

Market Cap

940.8M

Sector

Health Care

ML Signal

HOLD

Logo Aeva Technologies Inc.

AEVA

Aeva Technologies Inc.

HOLD

Current Price

$13.46

Market Cap

819.5M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSTL
AEVA
Founded
2007
2019
Country
United States
United States
Employees
N/A
276
Industry
Medical Specialities
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
940.8M
819.5M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
CSTL
AEVA
Price
$29.72
$13.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
4
Target Price
$46.67
$26.50
AVG Volume (30 Days)
390.1K
1.7M
Earning Date
05-18-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$344,229,000.00
N/A
Revenue This Year
$3.15
$87.55
Revenue Next Year
N/A
$70.04
P/E Ratio
N/A
N/A
Revenue Growth
3.66
N/A
52 Week Low
$14.59
$2.52
52 Week High
$44.28
$38.79

Technical Indicators

Market Signals
Indicator
CSTL
AEVA
Relative Strength Index (RSI) 33.66 46.42
Support Level $21.77 $12.54
Resistance Level $34.97 $14.30
Average True Range (ATR) 1.71 1.04
MACD -0.10 0.16
Stochastic Oscillator 31.72 49.48

Price Performance

Historical Comparison
CSTL
AEVA

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.

Share on Social Networks: